Real-World Data on the Use of Glecaprevir/Pibrentasvir in the Treatment of Hepatitis C: Is Shorter Treatment Possible?

Objectives: This study aimed to present real-world data on the efficacy of glecaprevir/pibrentasvir (G/P) in chronic hepatitis C (CHC) patients treated at our center.Materials and Methods: Non-cirrhotic, treatment-naive, and treatment-experienced (TN/TE) CHC patients with CHC who started G/P treatment in 2022 were included in this retrospective, cross-sectional, single-center, national study.Sustained virological response (SVR) was defined as undetectable hepatitis C virusribonucleic acid (HCV-RNA) for at least 12 weeks following the discontinuation of antiviral therapy.Results: Sixty patients with non-cirrhotic TN/TE CHC who started G/P were included in the study.All patients received G/P treatment for 8 weeks.The median age of the patients was 45 years (interquartile range 22-3) and 44 (73.3%) were males.The most frequently identified risk factor for CHC was substance use (n=7, 11.7%), whereas the most common comorbidities were cardiovascular disease, hypertension (n=8,13.3%),and diabetes mellitus (n=7, 11.7%).HCV genotype was evaluated in all patients.Genotype distribution: Genotype 1b was detected in 53 patients (88.3%) and genotype 1 was detected in 7 patients (11.7%).The median pretreatment HCV-RNA level of the patients was 137,000 IU/mL.HCV-RNA was evaluated in all patients at the 4 th and 8 th weeks of treatment and at the 12 th week after treatment.All patients were HCV-RNA-negative in the 1 st month of treatment. ÖZAmaç: Bu çalışmanın amacı, merkezimizde tedavi edilen kronik hepatit C (KHC) hastalarında glekaprevir/pibrentasvir (G/P) etkinliğine ilişkin gerçek dünya verilerini sunmaktır.Gereç ve Yöntemler: Bu retrospektif, kesitsel, tek merkezli, ulusal çalışmaya 2022 yılında G/P tedavisine başlayan sirotik olmayan, tedavi naif ve tedavi deneyimli (TN/TE) koroner kalp hastalığı (KKH) hastaları dahil edilmiştir.Kalıcı virolojik yanıt (KVY), antiviral tedavinin kesilmesini takiben en az 12 hafta boyunca tespit edilemeyen hepatit C virüsü-ribonükleik asit (HCV-RNA) olarak tanımlanmıştır